Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| AMGN | Amgen, Inc. | 1.46% | 243.82 | 1.3% | $795.90m | |
| IMMU | Immunomedics, Inc. | 0.07% | 85.36 | 11.0% | $697.18m | |
| MRNA | Moderna, Inc. | 6.60% | 69.47 | 0.0% | $666.49m | |
| NVAX | Novavax, Inc. | 10.86% | 113.56 | 96.5% | $629.01m | |
| ILMN | Illumina, Inc. | 4.74% | 299.89 | 3.5% | $582.79m | |
| GILD | Gilead Sciences, Inc. | 0.00% | 62.25 | 1.0% | $574.11m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.98% | 574.06 | 2.7% | $443.39m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 1.92% | 268.18 | 1.9% | $340.86m | |
| BIIB | Biogen, Inc. | 1.20% | 273.28 | 1.6% | $334.97m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 2.15% | 114.43 | 2.0% | $285.22m | |
| EXAS | EXACT Sciences Corp. | 3.60% | 97.70 | 20.7% | $257.29m | |
| SRNE | Sorrento Therapeutics, Inc. | 4.84% | 9.64 | 1.5% | $240.99m | |
| VXRT | Vaxart, Inc. | 7.40% | 7.40 | 0.0% | $213.88m | |
| SGEN | Seattle Genetics, Inc. | 3.08% | 184.95 | 6.0% | $212.14m | |
| MNTA | Momenta Pharmaceuticals, Inc. | 0.02% | 52.40 | 3.0% | $193.58m |
Company Profile
Fibrocell Science, Inc., is an autologous cell therapy company focused on the development of innovative products for aesthetic, medical and scientific applications. The fibroblast cell plays a key role in the production of collagen and growth factors which support the skin and other soft tissues; therefore, these cells could play a key role in treating many medical conditions. They have a robust pipeline and clinical programs based on the autologous fibroblast cell. They believe their aesthetic indication is a beachhead for higher value indications. They have a strong base of knowledge and expertise in cell based product development, manufacturing and seeking regulatory approvals. Their focus is to enter clinical programs to treat medical conditions that have an unmet need, helping patients and creating more value per cell.